Facebook X (Twitter) Instagram
    Facebook Instagram Threads
    Global BiodefenseGlobal Biodefense
    Subscribe
    • Featured News
    • Funding
    • Directory
    • Jobs
    • Events
    Global BiodefenseGlobal Biodefense
    Health Security

    Support the Development of the WHO Fungal Priority Pathogens List

    By Global Biodefense StaffOctober 9, 2020
    Collage of plated mixed culture of Candida glabrata (purple), Candida tropicalis (navy blue), and Candida auris (white, circled in red),
    Share
    Facebook LinkedIn Reddit Email

    WHO issues RFP to formalize effort for Fungal Priority Pathogens List of Public Health Importance

    Recognizing the public health threat of the global increase in burden of disease of fungal infections, coupled with existing treatability and resistance issues (both intrinsic and acquired), WHO is extending its efforts to develop a priority fungal pathogens list of public health importance and identify R&D priorities and gaps.

    The World Health Organization is developing the first WHO priority pathogens list of fungal pathogens of public health importance and the subsequent clinical antifungal pipeline analysis to be launched at the end of 2021.

    A virtual meeting of the antifungal expert group took place on 7 and 9 of April 2020 to discuss the methodology, pathogen selection and available evidence to begin the prioritization of fungal pathogens of global public health importance for which there is an urgent need for R&D for new treatments.

    There was overall consensus that the fungal pathogens initially set out by the WHO secretariat (Candida auris; azole-resistant Candida spp.; azole-resistant Aspergillus fumigatus; Cryptococcus neoformans & gattii; Pneumocystis jirovecii; Mucorales; and potentially Histoplasmosis) were all of global public health importance and should be evaluated based on limitations of treatment options due to resistance and/or existing treatability issues (e.g. Mucorales has limited treatment options and poor outcomes). Experts were in agreement that a longer initial list of fungal pathogens be drawn up which would then be prioritized and shortened.

    Other fungal pathogens that were mentioned for consideration include non-fumigatus Aspergillus spp, Fusarium, Coccidioides, Sporothrix, Blastomyces, Chromoblastomycosis, rare pathogens causing Chromablastomycosis and mycetoma (invasive), and even rarer moulds such as Lomentospora, Scedosporium and Talaromyces marneffei. It was suggested that the rare fungal infections that are either poorly treatable or untreatable could be captured in a separate group to highlight the need for compounds with activity against them.

    It was agreed that prioritization should consider not only availability of treatment, but also prevention strategies (infection prevention and control/prophylaxis), especially for pathogens with nosocomial relevance (e.g. for C. auris).

    There was a general agreement to limit the list to certain pathogens and invasive fungal infections and to consider clinical presentation as a criterion or sub-criterion. It was also suggested that the list be limited to health-care related infections due to challenges in obtaining data outside of that setting, however, no conclusion was reach on this matter.

    This week the WHO issued a formal request for proposals (RFP) seeking a qualified contractor to undertake systematic reviews, develop and conduct a multi-criteria decision analysis stakeholder survey, statistical analysis of the results and draft the WHO fungal priority pathogens list and subsequent clinical antifungal pipeline review.

    The activity will be coordinated by the WHO’s Global Coordination and Partnership on AMR Impact Initiatives and Research Coordination (IRC) unit and supported by a WHO expert advisory group.

    Additional details are available at the United Nations Global Marketplace. The proposal deadline is 28 October 2020.

    Antifungals Candida auris Editor Pick Fungal Infections Opportunities Request for Proposals Special Pathogens
    Share. Facebook LinkedIn Reddit Email
    Previous ArticleBARDA and JPEO-CBRND Back Cepheid’s Multiplex Test for Influenza, SARS-CoV2 and RSV
    Next Article NIH Funds a $9.3M Center for Precision Animal Modeling at UAB

    Related Stories

    EPA Developing AMR Risk Framework for Antibacterial and Antifungal Pesticides

    September 29, 2023

    Provide Feedback on Federal DURC Biosafety Oversight of Potential Pandemic Pathogens

    September 24, 2023

    Committee to Examine Transmission and Geographic Spread of Chronic Wasting Disease

    September 24, 2023

    Jurata Thin Film and CastleVax Awarded Grant to Advance Thermostabilized COVID-19 Booster

    September 20, 2023
    News Scan

    Biodefense Headlines – 19 September 2023

    News Scan September 19, 2023

    News highlights on health security threats and countermeasures curated by Global Biodefense This week’s selections include a global survey of gain-of-function research; funding of an mRNA mpox vaccine; Nipah virus outbreak in India; field detection of threat agents with acoustic…

    Upcoming Events

    Oct 3
    Virtual Event Virtual Event
    October 3 - October 5

    OneLab Summit 2023

    Oct 3
    Virtual Event Virtual Event
    12:00 pm - 2:00 pm EDT

    Public-Private Partnerships to Distribute, Dispense, and Administer Medical Countermeasures

    Oct 4
    Virtual Event Virtual Event
    10:00 am - 2:00 pm EDT

    Tunneling Nanotubes and Intracellular Protrusions Workshop

    Oct 12
    Virtual Event Virtual Event
    12:00 pm - 2:00 pm EDT

    Public-Private Partnerships for Acceptance and Uptake of Medical Countermeasures

    View Calendar

    Subscribe to Global Biodefense

    Get the latest news on pathogens and preparedness

    © 2023 Stemar Media Group LLC
    • About
    • Contact
    • Privacy
    • Subscribe

    Type above and press Enter to search. Press Esc to cancel.